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Abstract Acetylcholine (ACh), a classical transmitter of
parasympathetic nerve Wbres in the airways, is also synthe-
sized by a large number of non-neuronal cells, including
airway surface epithelial cells. Strongest expression of cho-
linergic traits is observed in neuroendocrine and brush cells
but other epithelial cell types—ciliated, basal and secre-
tory—are cholinergic as well. There is cell type-speciWc
expression of the molecular pathways of ACh release,
including both the vesicular storage and exocytotic release
known from neurons, and transmembrane release from the
cytosol via organic cation transporters. The subcellular dis-
tribution of the ACh release machineries suggests luminal
release from ciliated and secretory cells, and basolateral
release from neuroendocrine cells. The scenario as known
so far strongly suggests a local auto-/paracrine role of epi-
thelial ACh in regulating various aspects on the innate
mucosal defence mechanisms, including mucociliary clear-
ance, regulation of macrophage function and modulation of
sensory nerve Wbre activity. The proliferative eVects of
ACh gain importance in recently identiWed ACh receptor
disorders conferring susceptibility to lung cancer. The cell
type-speciWc molecular diversity of the epithelial ACh syn-
thesis and release machinery implies that it is diVerently
regulated than neuronal ACh release and can be speciWcally
targeted by appropriate drugs.
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Introduction
Acetylcholine (ACh) is a major regulator of airway func-
tion. In particular, it is one of the strongest known broncho-
constrictors and stimulators of secretion, but it is also
involved in regulating less acute mechanisms such as air-
way wall remodelling in disease and immunomodulation
(Gosens et al. 2004; Kummer and Lips 2006) (Fig. 1).
Accordingly, pharmacological manipulation of cholinergic
signalling, mostly inhibition, is a keystone in treatment of
common lung diseases, for example chronic obstructive
pulmonary disease (COPD) (Belmonte 2005; Gosens et al.
2006). The classical view on ACh in the respiratory system
is that of a neurotransmitter being released from parasym-
pathetic nerve Wbres that innervate airway smooth muscle
and glands. In addition, however, many non-neuronal cells
are capable of ACh synthesis and release, including such
diverse cell types such as keratinocytes, lymphocytes, pla-
cental trophoblast, endothelial cells and many more (for
reviews, see Wessler et al. 1998,  2001b). Non-neuronal
ACh is also present in the airway epithelium (Klapproth
et al.  1997; Proskocil et al. 2004; Kummer et al. 2006)
where it is believed to regulate cell proliferation (Metzen
et al. 2003) and to contribute to pathomechanisms underly-
ing COPD (Barnes 2004). Here, the pathways and mecha-
nisms of ACh synthesis, release, action and its termination
in the airway epithelium are reviewed. Particular emphasis
is given to highly cell type-speciWc modiWcations of these
mechanisms that potentially may allow to addressing selec-
tively non-neuronal and neuronal cholinergic signalling by
pharmacological intervention. Beforehand, a short over-
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view on airway epithelial cell types and neural and non-
neuronal ACh handling will be presented that is required
for understanding of the cell type-speciWc variants and their
potential meaning.
Tracheal and bronchial surface epithelial cell types
Altogether, at least 12 types of epithelial cells on the airway
surface and Wve types of epithelial cells in the airway
glands have been described, although some of these represent
diVerentiating or intermediate cells or are not recognizable
in all species (Robbins and Rennart 1997). Here, we
concentrate on the major surface epithelial cells. The hall-
mark of the respiratory epithelium is the ciliated cell that
generates the driving forces for mucociliary clearance, that
is cleaning of the airway surface from inhaled particles by
transporting a mucous layer towards the larynx. Ciliated
cells make up between 32 and 55% of total tracheal epithe-
lial cells in ten diVerent mammalian species (Pavelka et al.
1976), with higher relative numbers on the epithelial sur-
face at the tracheal ligaments (rat: 65%) and lower fre-
quency (rat: 32%) overlying cartilage rings (Oliveira et al.
2003). With rather little species variation, these ciliated
cells are columnar in the trachea and large bronchi (approx-
imately 20 m long and 7 m wide, tapering to 2 m at the
basement membrane) and then decrease in height towards
small bronchi and bronchioli (Lee and Forrest 1997).
Besides their characteristic beating cilia (6 m in length,
100–250 per cell), they also protrude microvilli
(1.8 £ 0.1 m) into the lumen (Hansell and Moretti 1969).
Their surface compartment contains the cystic Wbrosis
transmembrane conductance regulator (CFTR) protein,
whose mutation causes the common inherited disease cystic
Wbrosis (CF) (Puchelle et al. 1992). In the mouse, a species
with a general paucity of submucosal glands, expression of
human CFTR in ciliated cells of CFTR¡/¡ mice is capable
of correcting the airway defects in Cl¡ secretion and Na+
absorption (Ostrowski et al. 2007). In species such as pig
and human, where submucosal glands are present in signiW-
cant numbers, it is assumed that the bulk of the luminal
periciliary Xuid originates from these glands and ciliated
cells modify its ionic composition (Wu et al. 2007).
The carbohydrate-rich glycoproteins (“mucins”) and lip-
ids of the mucous layer are produced by submucosal glands
and, particularly in species with low numbers of such
glands, the second major surface epithelial cell type,
broadly designated “non-ciliated cells”. Their relative num-
ber, structure and secretory products change along the tra-
cheobronchial tree within a species, and among the tracheas
Fig. 1 Spectrum of actions of acetylcholine (ACh) in the airways. In
cases where ACh may cause opposing eVects, dependent on receptor
subtype being involved, the term is written both in green and red colour
(e.g. collagen synthesis by Wbroblasts). Adopted and extended from
Kummer and Lips (2006), incorporating recent Wndings by ProWta
et al. (2008) and Haag et al. (2008)Histochem Cell Biol (2008) 130:219–234 221
123
between species according to tracheal diameter. Classical
goblet cells account for 9% in the human trachea and are
practically absent from human distal bronchioli and mouse
trachea (Pavelka et al. 1976). Smaller airways such as
human bronchioli and mouse trachea contain cells with pro-
truding apical region decorated with few microvilli, abun-
dant smooth or rough (dependent on species) endoplasmic
reticulum, and secretory granules smaller than those found
in goblet cells (Pavelka et al. 1976; Plopper et al. 1980). In
distal airways, they are often referred to as Clara cells, in
the trachea of small mammals such non-ciliated cells have
also been termed secretory cells or mucous cells. Certainly,
these cells do not comprise a homogenous population. In
the present review, however, they will be collectively
referred to as “secretory cells” since no distinction between
subtypes has so far been made with respect to reports on
epithelial ACh synthesis or action.
Basal cells, not facing the lumen, are found in larger air-
ways only and account for 20% (mouse, hamster)–32%
(horse, human) of tracheal epithelia cells (Pavelka et al.
1976).
Besides these most frequent cell types, there are specialized
epithelial cells rather infrequent in number but particularly
conspicuous in their expression of cholinergic traits.
Pulmonary neuroendocrine cells develop from a diVerent
group of precursors than those forming the peripheral sub-
set of respiratory epithelial cells (Perl et al. 2002). They
either occur solitarily within the airway epithelium
(Fig. 2a), or are clustered as neuroepithelial bodies (NEBs)
preferentially at bronchial branchings (Linnoila 2006).
Their development is diVerentially controlled since targeted
disruption of NeuroD, a proneural bHLH factor, results in
an increased number of NEBs but a reduced number of soli-
tary pulmonary neuroendocrine cells in the neonatal mouse
lung (Neptune et al. 2008). They share the presence of
dense core granules that store bioactive amines and neuro-
peptides and are located in the basal compartment (Fig. 2c).
NEBs are present in great numbers before birth and during
the neonatal period and are generally believed to contribute
to lung maturation, and to function as oxygen sensors com-
plementing the maturing carotid body (Linnoila 2006). The
oxygen sensor function, however, has also been questioned
and the idea has been posed that the diVerent populations of
myelinated vagal aVerents that selectively innervate intra-
epithelial pulmonary NEBs may represent subpopulations
of the extensive group of known electrophysiologically
characterized myelinated mechanosensitive vagal airway
receptors (Adriaensen et al. 2006). The role of solitary pul-
monary neuroendocrine cells is also not fully clear. Pro-
posed roles in fetal and newborn lung development include
regulation of branching morphogenesis as well as cellular
growth and maturation. In adult mice, they are associated
Fig. 2 Ultrastructure of neuro-
endocrine (E) and brush (B) cells 
in the mouse trachea. a An endo-
crine cell is situated next to a 
secretory (S) and ciliated (C) 
cell. Its apical microvilli are less 
densely packed than those of a 
brush cell (B in b). c Endocrine 
cells are characterized by large 
(ca. 100 nm) dense-core gran-
ules in their basal cytoplasma; M 
mitochondrium. d In brush cells, 
Wlament bundles (F) extend 
from the bundle of microvilli 
into the apical cytoplasm. The 
cytoplasm is rich in tubulovesic-
ular structures which currently 
have not been fully 
characterized222 Histochem Cell Biol (2008) 130:219–234
123
with stem cell niches in both the proximal and distal air-
ways, and it has been proposed that they foster a microenvi-
ronment resistant to destruction of environmental agents
and promoting stem cell renewal (Linnoila 2006). Clini-
cally important, pulmonary neuroendocrine cells can give
rise to a malignant tumour, the small cell lung carcinoma
(Linnoila 2006).
Finally, an equally infrequent cell type is characterized
by an apical brush of microvilli (Fig. 2b, d) and, accord-
ingly, termed “brush cell”. Tracheobronchial brush cells
express components of the taste-signalling cascade and,
consequently, are considered to act as chemosensory cells
(Kaske et al. 2007; Merigo et al. 2007; Osculati et al.
2007). The interesting hypothesis has been posed that they
may sense bacterial colonization and serve to initiate
defence mechanisms (Sbarbati and Osculati 2006).
ACh synthesis and recycling in cholinergic nerve Wbres
The cation ACh is synthesized in the axoplasm by choline
acetyltransferase (ChAT) from choline and acetyl-CoA
being generated in mitochondria (Fig. 3). To allow for ACh
synthesis suYcient for synaptic transmission, the essential
nutrient choline has to be taken up from the extracellular
space. This uptake is the rate-limiting step in neuronal ACh
synthesis and it is achieved by a high-aYnity choline trans-
porter (CHT1) that has been cloned and is pharmacologi-
cally characterized by its sensitivity to hemicholinium-3
and dependency on sodium (Okuda et al. 2000; Apparsun-
daram et al. 2001). Once being generated in the axoplasm,
ACh is translocated into small (about 45 nm in diameter)
synaptic vesicles via the vesicular acetylcholine transporter
(VAChT), a 12 transmembrane domain protein acting as a
H+/ACh exchanger (Parsons 2000). The interior of these
vesicles binds up to 10,000 molecules of ACh via a matrix
enriched with the synaptic vesicle proteoglycan SV2 (Reig-
ada et al. 2003). Depolarization of the nerve terminal trig-
gers exocytotic release of ACh from these vesicles, during
which the “smart gel matrix” of the vesicles releases neuro-
transmitter and changes its volume when challenged with
small ionic concentration change (Reigada et al. 2003;
González-Sistal et al. 2007). Extracellular ACh acts via two
classes of cholinergic receptors: Metabotropic muscarinic
receptors (MR, Wve isotypes are known: M1–M5) are G
protein-coupled receptors with seven transmembrane
domains, and ionotropic nicotinic acetylcholine receptors
(nAChR) are cation channels with two ACh binding sites,
being formed as hetero- or homopentamers consisting of a
high diversity of subunits (Lukas et al. 1999; Wess et al.
2007). The action of ACh is rapidly terminated and spa-
tially limited by cleavage into acetate and choline through
the extremely eYcient enzyme, ACh esterase (AChE). This
enzyme is synthesized by cholinergic neurons themselves
thereby ensuring that the localization of neuronal ACh
release matches that of ACh degrading capacity. Choline is
taken up again at the nerve terminal via CHT1, and a new
cycle of ACh synthesis and release is to begin (Fig. 3).
ACh synthesis and recycling in non-neuronal cells
Phylogenetically, non-neuronal ACh synthesis is the older
system, as it can be found already in bacteria and plants
(Wessler et al. 1999). Some of the particularly eYcient
enzymes and transporters of cholinergic neurons have
evolved comparatively recently and are not found through-
out the non-neuronal cholinergic system. Instead, less
eYcient mechanisms of ACh synthesis, storage and release
dominate, although not exclusively (Fig. 4). So, each cell
does contain uptake mechanisms for choline which are
indeed necessary for cellular survival because of the need
of choline for synthesis of plasma membrane lipids, in par-
ticular phosphatidylcholine. There is a great variety of
plasma membrane choline transporters (Michel et al. 2006),
and only few cholinergic non-neuronal cells do express the
high-aYnity choline transporter CHT1 (e.g. Pfeil et al.
2003). An alternative route for ACh synthesis is provided
by carnitine acetyltransferase (CarAT) which, albeit in
principle less eYcient than ChAT, drives ACh synthesis in
skeletal muscle Wbres (Tucek 1982) and is present in the
urothelium where ACh is found in absence of ChAT
Fig. 3 Recycling pathway of acetylcholine (ACh) synthesis, release,
action and breakdown at a cholinergic nerve terminal. AChE acetyl-
cholinesterase, BChE butyrylcholinesterase, ChAT choline acetyltrans-
ferase,  CHT1 high-aYnity choline transporter-1, M muscarinic
receptor, G-protein coupled, N nicotinic receptor, ligand-gated ion
channel, VAChT vesicular ACh transporterHistochem Cell Biol (2008) 130:219–234 223
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(Lips et al. 2007a). VAChT and vesicular storage mecha-
nisms for ACh also have not been found regularly in non-
neuronal cholinergic cells, implying direct release of ACh
from the cytoplasm instead via exocytosis. Indeed, use of
pharmacological inhibitors and siRNA provided evidence
for ACh release via plasma membrane-bound polyspeciWc
organic cation transporters (OCT) 1 and 3 (Wessler et al.
2001a), and ACh transport both inside and outside of cells
could be directly demonstrated in Xenopus oocytes trans-
fected with either OCT1 or 2 (Lips et al. 2005). These elec-
trogenic transporters are bidirectional and their driving
forces are substrate concentration and membrane potential
(Koepsell et al. 2007).
A proteolipid called “mediatophore” has been originally
described in plasma membranes of the electric organ of the
electric ray, torpedo marmorata, where it serves to release
ACh either directly from the cytoplasm or by forming the
fusion pore between the synaptic vesicle and the plasma
membrane (Morel 2003). The mammalian homologue is
part of the vacuolar H+-ATPase (V–ATPase, V0 subunit c)
that is predominantly targeted to acidic organelles such as
lysosomes, endosomes and secretory vesicles (Morel
2003). Mammalian non-neuronal cells transfected with
ChAT gain the property to release ACh only when they are
co-transfected with this proteolipid and when it is targeted
to the plasma membrane (Bloc et al. 1999; Morel 2003).
Interestingly, the V–ATPase complex is localized to the
plasma membrane in human lung microvascular endothelial
cells (Rojas et al. 2004) and rabbit alveolar macrophages
(Heming and Bidani 2003), so that “mediatophore” may
mediate ACh release from these cells.
Microdialysis experiments on human skin demonstrated
that there are other, currently not identiWed mechanisms of
non-neuronal ACh release as well (Schlereth et al. 2006).
Once released, ACh can be cleaved by esterases being less
speciWc than AChE, the most prominent one being butyrylch-
olinesterase (BChE) (Darvesh et al. 2003) (Fig. 4).
Choline transporters in the airway epithelium
The high-aYnity choline transporter CHT1, known from
the nervous system, has been localized to the apical mem-
brane of the ciliated cell in the rat trachea, and this Wnding
has been validated by in situ-hybridization, Western blot-
ting of abraded tracheal epithelium, and RT-PCR of tra-
cheal epithelium obtained by laser-assisted microdissection
(Pfeil et al. 2003). CHT1-immunolabelling, supported by
RT-PCR of scraped epithelium, has also been reported for
monkey (rhesus macaques) bronchial epithelium (Proskocil
et al. 2004), in this case without further speciWcation of epi-
thelial cell type and subcellular distribution. Functional
studies on the bronchial adenocarcinoma cell line A549
also demonstrated a sodium-dependent choline uptake with
the characteristics of CHT1 (Kleinzeller et al. 1994). Col-
lectively, these data strongly indicate that there is high-
aYnity uptake of choline from the airway lining Xuid into
ciliated cells via a transport system that originally has been
thought to be speciWc for neurons.
These data alone, however, do not explain how choline
enters the airway lining Xuid at Wrst hand, and how other
epithelial cholinergic cells, lacking CHT1, fuel their ACh
synthesis. As expected, airway epithelial cells express addi-
tional choline transport systems, and they may operate
alone or in parallel with CHT1 in speciWc cell types. A549
cells coexpress at least two choline transport systems, one
with CHT1 characteristics (Km of 4 M), and a sodium-
independent with a Km of approximately 44 M that is
dependent on a transmembrane H+ gradient, is relatively
insensitive to hemicholinium-3, and is amiloride sensitive
(Kleinzeller et al. 1994).
Choline transporters besides CHT1 can be largely classi-
Wed into the families of choline-speciWc transporter-like
proteins (CTL family) and polyspeciWc organic cation
transporters (OCT family) (Michel et al. 2006). Members
of both families are expressed in the lung. CTL1, the main
member of the CTL family (TraiVort et al. 2005), is
detected by Western blotting in total human but not mouse
lung extracts (Michel et al. 2006), expressed in A549 cells
and contributes predominantly to choline uptake in this cell
line (Wang et al. 2007; Ishiguro et al. 2008). Its in situ dis-
tribution in human airways, as determined by immunohisto-
chemistry or in situ-hybridization, has not been investigated
yet. In the rat lung, CTL2 and CTL4 are abundantly
Fig. 4 Summary of recycling pathways of acetylcholine (ACh) syn-
thesis, release, action and breakdown at a non-neuronal cell. CarAT
carnitine acetyltransferase, OCTs organic cation transporters. Other
abbreviations as in Fig. 3224 Histochem Cell Biol (2008) 130:219–234
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expressed (TraiVort et al. 2005) but their cellular distribu-
tion is unknown.
Among the polyspeciWc OCT family members, OCT1
and OCT2, but not OCT3, OCTN1 and OCTN2, do trans-
port choline (Busch et al. 1996; Wu et al. 1998,  1999;
Sweet et al. 2001). OCT1 is expressed in the mouse, rat and
human bronchial epithelium, and immunohistochemistry
showed a predominant localization in the apical membrane
of ciliated cells but intracellular pools of immunoreactive
OCT1 were also detectable (Lips et al. 2005,  2007b;
Kummer et al. 2006). At least in rat, OCT1 expression in
the airway epithelium is cell type-speciWc in that OCT1-
immunoreactivity is selective for ciliated cells but absent in
secretory, brush and basal cells (Lips et al. 2005). The spec-
iWcity of OCT1-immunolabelling was validated by its
absence in the respective knockout mouse strain (Kummer
et al. 2006). OCT2 is expressed in human and rat but not
mouse bronchial epithelium (Lips et al. 2005; Kummer
et al. 2006). In human bronchi, OCT2-immunoreactivity is
predominant in the luminal membrane of ciliated cells,
weakly present in basal cell membranes, and absent from
goblet cells (Lips et al. 2005). In OCT1/2 double-knockout
mice, tracheal epithelial ACh content is signiWcantly ele-
vated instead of being reduced (Kummer et al. 2006). Thus,
although OCT1 and 2 are capable of choline translocation
across the plasma membrane, they are obviously not crucial
for providing choline for epithelial ACh synthesis.
In conclusion, there is a multiplicity of choline uptake
systems in airway epithelial cells with a cell type-speciWc
distribution and a distinct apical versus basolateral polari-
zation. Functional studies indicate prominent roles for
CHT1 and CTL1. Further detailed understanding of cellular
choline transport in the respiratory epithelium will require
detailed investigation of the cellular distribution and intra-
cellular targeting of the members of the CTL family.
ACh synthesis in the airway epithelium
The presence of both choline acetyltransferase activity as
well as of the product ACh itself have been undoubtedly
demonstrated within the respiratory epithelium by bio-
chemical methods (Klapproth et al. 1997; Reinheimer et al.
1998; Kummer et al. 2006). Accordingly, the airway epi-
thelium has been reported to be labelled by ChAT antisera
(Klapproth et al. 1997; Canning and Fischer 1997; Prosko-
cil et al. 2004). The real identity of the ACh synthesizing
enzyme in the individual epithelial cell types; however, is
much less clear than it might appear from these apparently
coherent pieces of information. First, it has to be noted that
there is a great diversity of ChAT variants, all deriving
from the same gene. These diVerences are so marked that
antisera directed against ChAT of central nervous system
neurons mostly do not react with ChAT produced by
peripheral autonomic neurons which rendered a thorough
investigation of peripheral cholinergic neurons diYcult for
a long time and, of course, also that of the non-neuronal
cholinergic system.
The mammalian ChAT gene contains three non-coding
exons (termed R-, M- and N-exon in the rat and mouse)
and, depending on species, 15–16 coding exons (Fig. 5A).
The intron-less gene coding for VAChT is inserted between
the Wrst two non-coding ChAT exons, i.e. the R- and
N-exon, and this peculiar gene structure coding for ChAT
and VAChT is designated the “cholinergic gene locus”
(Erickson et al. 1994). Alternative transcription starts and
splicing result in diversity of mRNAs diVering in their
5-non-coding region. In the rat, Wve variants are known
(Fig. 5a), seven in the mouse and more than six in human
(Misawa et al. 1992; Robert and Quirin-Stricker 2001;
Ohno et al. 2001).
In the central nervous system, all of these variants are
expressed with the M-type ChAT-mRNA usually dominat-
ing. We have addressed the question which of these vari-
ants is expressed in the rat tracheal epithelium by RT-PCR,
and identiWed solely M-type ChAT-mRNA whereas all Wve
variants were expressed in the spinal cord (Fig. 5b). In
scrapings of monkey (rhesus macaques) bronchial epithe-
lium, expression of non-coding exons N and S was identi-
Wed (Proskocil et al. 2004).
In the rat and mouse, all of the mRNA variants of the
non-coding region code for the same 69 kDa protein, so
that the functional meaning of this diversity might lie in
diVerences in mRNA stability but this issue is not fully
understood. In humans, an N-terminally extended 82 kDa
ChAT protein variant results from H-type mRNA (Robert
and Quirin-Stricker 2001), and this ChAT variant localizes
preferentially to the nucleus (Resendes et al. 1999). DiVer-
ent ChAT protein variants can also result from alternative
splicing in the coding region. Removal of exons 6–9 results
in ChAT of peripheral autonomic neurons (pChAT) as
opposed to the more commonly found 69 kDa ChAT (com-
mon ChAT = cChAT; Tooyama and Kimura 2000). Per-
forming RT-PCR, we identiWed full-size cChAT mRNA in
the rat tracheal epithelium whereas we were unable to
detect pChAT mRNA (Fig. 5c). Thus, at mRNA level the
presently available data of the rat trachea show at least a
clear dominance, if not even exclusive expression, of a sin-
gle M-type cChAT mRNA that shall encode for a 69 kDa
protein.
We have raised antibodies against a 14 amino acid
stretch located in the rat cChAT speciWc sequence (posi-
tions 282–295 of the predicted sequence), and against a
peptide of 10 amino acids spanning amino acids 138–141
of exon 5 and amino acids 352–357 of exon 10 which in
this sequence shall be unique for pChAT (Pfeil et al. 2004).Histochem Cell Biol (2008) 130:219–234 225
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In immunohistochemistry, the cChAT-antiserum labelled
all epithelial cell types of the rat trachea, and preabsorption
of this antibody with the corresponding peptide abolished
immunolabelling (Fig. 6a, b). These Wndings were sup-
ported by in situ-hybridization (Fig. 6c, d). In more distal
airways, cChAT-immunolabelling of ciliated and secretory
cells was generally less intense than in the trachea, whereas
endocrine cells and brush cells were particularly cChAT-
immunolabelled (Fig. 6e, f). Within tracheal ciliated cells, a
more intense labelling of the apical cytoplasmatic region
was noted, consistent with an earlier report on human bron-
chi (Klapproth et al. 1997). Thus, in these cells cChAT is
located close to the high-aYnity uptake system for choline,
that is CHT1 (see above), thereby concentrating the entire
ACh synthesizing machinery at the apical aspect of the cili-
ated cell suggesting luminal release.
These data together with the RT-PCR results suggest a
rather homogenous expression of a single variant of ChAT,
that is ChAT translated from M-type ChAT mRNA, in vari-
ous airway epithelial cell types. There are, however, quite
several data on protein level that point to a more complicated
situation. Klapproth and coworkers (1997) reported immuno-
histochemical ChAT-labelling of human bronchial epithe-
lium with an antibody that recognized 54 and 41 kDa
proteins in bronchial epithelial extracts. ChAT protein vari-
ants of this molecular weight can not be explained by our
current understanding of ChAT mRNA splicing and post-
translational processing. Using our pChAT-antiserum, we
obtained strong immunohistochemical labelling of the same
cell types that reacted with the cChAT-antiserum in the rat
trachea. These data were not supported by RT-PCR. Such a
striking discrepancy between clear detection of a pChAT-
immunoreactive protein and lack of detectable mRNA—or
need to use nested RT-PCR—has been reported before also
for the rat placenta (Pfeil et al. 2004) and retina (Yasuhara
et al. 2004). In neither case, it has been resolved whether this
originates from vastly diverse life-times of mRNA and pro-
tein, respectively, or from technical problems (false positive
protein data or false negative mRNA data). In particular, it
shall be taken into account that immunohistochemical label-
ling may be due to cross reaction with a closely related or
even unrelated protein, even if it can be successfully preab-
sorbed with the corresponding antigen, as recent studies on
knockout strains have drastically shown (Moser et al. 2007).
Fig. 5 Choline acetyltransferase (ChAT) variants. a Structure of the
“cholinergic gene locus” in the rat. The ChAT gene consists of three
non-coding (R, N, M) and 15 coding exons. Use of diVerent transcrip-
tion starts (*) and alternative splicing results in 5 variants of ChAT-
mRNA (R1 to M) diVering in the non-coding region. Alternative splic-
ing in the coding region results in common or peripheral type of ChAT.
The intron-less gene of the vesicular acetylcholine transporter
(VAChT) is located in the Wrst intron of the ChAT gene. ModiWed from
Misawa et al. (1995) and Tooyama and Kimura (2000). b RT-PCR, rat.
In abraded rat tracheal epithelium, M-type ChAT mRNA is exclusively
expressed whereas all Wve types of non-coding variants are detected in
the spinal cord. c RT-PCR, rat. Full-length common ChAT mRNA is
expressed in rat abraded tracheal epithelium and lung. Spinal cord
served as positive control. GAPDH glyceraldehyde phosphate dehy-
drogenase, M marker, H2O control run without template226 Histochem Cell Biol (2008) 130:219–234
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Clear support for ChAT expression in at least a subpopu-
lation of airway epithelial cells comes from a ChATBAC–
eGFP reporter mouse strain (Tallini et al. 2006). Slender
eGFP expressing epithelial cells are situated in the airway
epithelium, and these cells are not labelled with a synapto-
physin-antibody, a marker for neuroendocrine cells (Tallini
et al. 2006). Considering that (1) villin-positive brush cells
are intensely ChAT-immunoreactive (Fig. 5), (2) exhibit
many characteristics of taste cells (Sbarbati and Osculati
2005; Kaske et al. 2007), and (3) taste cells of the tongue
express eGFP in this mouse strain (Ogura et al. 2007), it is
highly likely that these eGFP expressing cells are airway
brush cells.
ACh release machinery in the airway epithelium
In neurons, VAChT shuZes ACh from the axoplasm into
synaptic vesicles (Fig. 2). The intron-less VAChT gene is
inserted into the non-coding region of the ChAT gene
(Fig. 5), and this peculiar arrangement has been interpreted
to orchestrate coordinate expression of ChAT and VAChT
(Misawa et al. 1995). In abraded or laser-microdissected
airway epithelium, VAChT mRNA is readily detectable
(Lips et al. 2005). Notably, it is assumed that expression of
VAChT mRNA will not necessarily lead to detectable lev-
els of VAChT protein, because VAChT mRNA is detected
in some cells where VAChT protein remained undetectable
(Dolezal et al. 2001). In the airway epithelium, VAChT-
labelling has been demonstrated by immunohistochemistry
in monkey bronchi without further assignment to speciWc
cell types (Proskocil et al. 2004), in secretory cells of the
rat trachea (Lips et al. 2005), and neuroepithelial bodies in
rat bronchi (Adriaensen et al. 2003). Correspondingly,
human small cell lung carcinoma cell lines, derived from
airway neuroendocrine cells, express VAChT along with
ChAT, and ACh release from these cells is sensitive to
vesamicol, a VAChT inhibitor (Song et al. 2003).
Ciliated cells, however, apparently utilize a non-vesicu-
lar ACh release mechanism. OCT1 and OCT2 are localized
at the apical membrane of ciliated airway epithelial cells,
and OCT3 is localized at the basolateral membrane of
several cell types in human bronchial epithelium (Lips et al.
2005). Xenopus oocytes transfected with either OCT1 or 2
of rat and human sequence, respectively, indeed translocate
Fig. 6 Common type of choline acetyltransferase (cChAT) in rat air-
way epithelium. a An antibody raised against a synthetic peptide
unique to cChAT (Pfeil et al. 2004) labels the rat tracheal epithelium.
Secretory cells and ciliated cells are identiWed by their characteristic
morphology and are particularly labelled in their supranuclear region.
b Corresponding region to a. Preabsorption of the antiserum with
cognate peptide results in absence of immunolabelling. c Rat trachea.
In-situ hybridization for cChAT supports immunohistochemistry in
that the epithelial layer is labelled throughout. d Corresponding region
to C, sense control. e, e’ Rat bronchus, double-labelling immunoXuo-
rescence. Overall, cChAT-immunolabelling is less intense than in tra-
chea. A solitary distinctly cChAT-immunoreactive cell is identiWed as
brush cell by its immunoreactivity to villin. f, f’ Rat bronchus, double-
labelling immunoXuorescence. A solitary distinctly cChAT-immuno-
reactive cell is identiWed as neuroendocrine by its immunoreactivity to
PGP9.5
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ACh across the plasma membrane, the direction (release or
uptake) being determined by concentration gradient and
membrane potential (Lips et al. 2005). In the mouse tra-
cheal epithelium, ACh content is signiWcantly elevated in
OCT1/2 double-knockout mice, providing evidence that
these polyspeciWc transporters are involved in epithelial
ACh release in vivo (Kummer et al. 2006). The apical
localization of OCT1/2 in airway ciliated cell Wts well with
the concentration of the high-aYnity choline transporter
and the ACh synthesizing enzyme ChAT in the same cellu-
lar domain, strongly suggesting a complete cycle of ACh
synthesis, release and reuptake of choline between the cili-
ated cell and the luminal airway lining Xuid.
The role of OCT3 in the basolateral membrane of vari-
ous airway epithelial cell types remains unclear at current.
Release of ACh from isolated human placental villi is sig-
niWcantly diminished by targeting OCT3 with antisense
strategy (Wessler et al. 2001a). In contrast, rat or human
OCT3 expressed by Xenopus oocytes do not translocate
ACh (Lips et al. 2005). Possibly, OCT3 requires expression
of additional proteins to serve as an ACh transporter.
These polyspeciWc transporters are the target of numerous
drugs which either compete with transport of other cations or
block transport without being transported themselves. Rele-
vant for airway pharmacology, nicotine and corticosteroids
(corticosterone, Xuticasone, budesonide) block ACh release
by OCT1 and 2 in vitro (oocyte expression system) (Lips
et al. 2005). Thus, inhibition of non-neuronal ACh release is
a just recently discovered non-genomic eVects of corticoste-
roids that clearly discriminates non-neuronal from neuronal
cholinergic mechanisms in the airways.
The occurrence and distribution of “mediatophore” in
the airway epithelium has not been investigated yet.
Collectively, the presently available data suggest the fol-
lowing scenario of ACh release in the respiratory epithelium:
vesicular basal release by neuroendocrine and possibly brush
cells, vesicular luminal release by secretory cells, and apical
concentration- and membrane potential-driven transmem-
brane release from the cytoplasm of ciliated cells (Fig. 7).
ACh degradation in the airway epithelium
Neuronal cholinergic transmission is rapidly terminated by
enzymatic cleavage of ACh into acetate and choline by
AChE (Fig. 2). This enzyme operates at an extremely high
turnover rate, thereby limiting ACh action very eVectively
both spatially and in time (Rosenberry 1975). The physio-
logical necessity for such a rapid termination of cholinergic
transmission is underlined by the very short postnatal sur-
vival period (about 2 weeks spontaneously, up to 100 days
under special dietary conditions) of AChE gene-deWcient
mice (Duysen et al. 2002). Besides AChE, there are addi-
tional other, less speciWc esterases cleaving ACh, the most
prominent one being BChE (Fig. 2).
In light of such a rapid extracellular degradation of ACh,
the physiological relevance of the epithelial cholinergic
system has been questioned because of the following con-
siderations: The amount of ACh generated in the airway
epithelium is low compared to that produced by neurons. In
FVB mice, for example, epithelial ACh content amounts to
only 17% of that of the entire tracheal wall (Kummer et al.
2006), and the true diVerence in intracellular concentration
between airway epithelial cells and tracheal cholinergic
nerve Wbres is even manifold higher since the latter may
make up about 1% of tissue volume but contain approxi-
mately 80% of tracheal ACh. Moreover, release of ACh
from the dominating epithelial cell type is via transmem-
brane transport, as reviewed in the preceding chapter, and
not via exocytosis that allows for release of approximately
10,000 molecules of ACh per single vesicle. Thus, extracel-
lular concentration of ACh released from epithelial cells is
expected to be orders of magnitude lower than that in the
surrounding of stimulated cholinergic nerve Wbres. This
assumption is supported by direct measurements. There are
only two successful examples of direct measurement of
non-neuronal ACh release into surrounding tissue in vivo
(human skin, microdialysis technique; Schlereth et al.
2006, 2007) or into culture medium from freshly isolated
biopsies (human placental villi: Wessler et al. 2001a)
whereas on most epithelial surfaces, including airway
mucosa, only intracellular but not extracellular levels reach
concentrations above threshold of detection. Hence, rele-
vant paracrine eVects of ACh indeed have to be questioned
in case of the presence of an eVective extracellular ACh
Fig. 7 Schematic drawing of acetylcholine (ACh) release mechanisms
from airway surface epithelium cell types. In the brush cell, the direc-
tion of vesicular exocytotic release has not been Wnally identiWed yet.
CHT1 high-aYnity choline transporter-1, OCT organic cation trans-
porter, VAChT vesicular acetylcholine transporter. ModiWed from
Kummer and Lips (2006) and extended
ACh
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Ac-CoA
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degrading system in the mucosa. Alternatively, it has been
suggested that ACh might have intracellular eVects by tar-
geting intracellular receptors (Wessler et al. 2001b).
It appears, however, that the epithelial ACh degrading
capacity is low, thereby probably enabling paracrine ACh
signalling at low concentrations. Scrapings of guinea-pig tra-
cheal epithelium did not hydrolyse ACh (Small et al. 1990),
and only a low AChE activity (117 mU/mg of epithelial seg-
ment) was reported for supernatants of mechanically dis-
sected sheets of porcine tracheal mucosa (Chen et al. 2005)
which may also contain subepithelial nerve Wbres. Only 40%
AChE activity was blocked by neostigmine, a potent AChE
inhibitor, suggesting that the majority of this activity is not
due to authentic AChE (Chen et al. 2005). Indirect pharma-
cological approaches operating with various inhibitors and
epithelium-intact and epithelium denuded preparations also
did not provide evidence for substantial AChE activity in the
airway epithelium (Koga et al. 1992; Degano et al. 2001).
One electronmicroscopic histochemical study revealed
cholinesterase activity associated with the endoplasmic
reticulum located around the basal bodies of cilia in the rat
trachea and nasal septum (Graf and Stockinger 1966), and a
modiWed histochemical AChE staining method using
increased substrate concentrations resulted in granular
labelling of putative neuroendocrine cells in fetal rat air-
ways in vitro (Morikawa et al. 1978). However, subsequent
histochemical studies aimed to demonstrate speciWcally
AChE and BChE, respectively, revealed AChE activity of
nerve Wbres predominantly innervating the airway smooth
muscle and BChE activity of the smooth muscle cells them-
selves (human: Partanen et al. 1982; rat: Small et al. 1990;
Ohrui et al. 1991; mouse: Fig. 8).
In conclusion, there is little if any ACh degrading capacity
in the airway epithelium which may allow for auto/paracrine
eVects of small amounts of ACh released by epithelial cells.
Targets and function of the epithelial cholinergic system
Non-neuronal cholinergic cells are generally assumed to act
in an auto/paracrine manner (Wessler et al. 1998). As
judged from the subcellular distribution of the ACh releas-
ing machinery, it can be anticipated that secretory and cili-
ated cells release ACh into the luminal periciliary Xuid,
whereas endocrine, and possibly basal cells as well, shall
secrete ACh basally. Currently, there are no direct clues as
to the direction of ACh release from brush cells (Fig. 7).
Luminally released ACh can reach a limited number of
cell types only. On one hand, it has access to the luminal
aspects of the epithelial cells themselves. On the other,
macrophages and to a much lesser extent other cells of the
immune system patrol in the mucus layer. Both airway epi-
thelial cells and macrophages carry a variety of muscarinic
and nicotinic receptors and, hence, are potential targets of
locally released ACh. Epithelial cells express muscarinic
receptors M1 and M3, and most of the - and -subunits of
nAChR (Proskocil et al. 2004; Sekhon et al. 2005; Fig. 9).
Our understanding of cell type speciWc cholinergic eVects
in the respiratory epithelium would beneWt greatly from
detailed knowledge of the distribution of cholinergic recep-
Fig. 8 Histochemical demonstration of acetylcholine degrading
enzymes in the mouse trachea. Acetylcholinesterase (AChE) activity is
located on nerve Wbres penetrating the smooth muscle (SM), which by
itself exhibits butyrylcholinesterase (BChE) activity. E Epithelium
Fig. 9 Expression of multiple nicotinic acetylcholine receptor sub-
units in the abraded rat tracheal epithelium, RT-PCR. -Subunits 2, 3,
4, 5, 7 and 10 are strongly expressed, subunit 6 is weakly expressed
and subunit 9 is missing. GAPDH glyceraldehyde phosphate dehy-
drogenase, M marker, ØRT control run without reverse transcription,
H2O control run without templateHistochem Cell Biol (2008) 130:219–234 229
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tors, both at cellular level (which cell type carries which
receptor?) and subcellular level (apical versus basolateral
localization of receptors in the cell membrane). Unfortu-
nately, there is only very limited information available
since all antibodies directed against nAChR subunits and
M1 and M3 receptors tested so far are prone to unspeciWc
staining as indicated by controls performed on respective
gene-deWcient mice (Herber et al. 2004; Moser et al. 2007;
Zarghooni et al. 2007). Hence, it is established that ACh
regulates epithelial cell proliferation, mucus secretion,
chloride ion secretion, release of GM-CSF and interleukin-
8, and stimulates ciliary beat frequency (for review, see
Kummer and Lips 2006) but which of these eVects may be
exerted by ACh released from the epithelium and acting
upon apical receptors is not fully resolved yet.
Alveolar macrophages express M3 receptors as well as
nAChR subunits (Sato et al. 1998; Matsunaga et al. 2001;
Galvis et al. 2006; Biallas et al. 2007; Mikulski et al. 2007).
Stimulation of M3 receptors causes cultured bovine alveo-
lar macrophages to release inXammatory cell activity (Sato
et al. 1998), whereas stimulation of nAChR has a suppres-
sive eVect on alveolar macrophages (Matsunaga et al. 2001;
Blanchet et al. 2006) and a general anti-inXammatory eVect
in the lung (Blanchet et al. 2004; Su et al. 2007). Outside
the lung, this nicotinic anti-inXammatory eVect on macro-
phages has been ascribed to nAChR consisting of the 7-
subunit (Wang et al. 2003) but independent groups failed to
detect this subunit in alveolar macrophages (Matsunaga
et al. 2001; Mikulski et al. 2007), and from the presence of
subunit expression and pharmacological characteristics an
9/10-subunit composition appears to be most likely.
Based upon their localization in the airway lumen, alveolar
macrophages are separated from neurally released ACh
and, hence, are a highly likely a target of luminal ACh
released from airway epithelial cells (Fig. 10).
Basolaterally released ACh, in principle, has the potential
to evoke any of the numerous eVects on any cell type of the
airway wall depicted in Fig. 1. A clear distinction between
cholinergic eVects evoked by epithelial and those evoked by
neuronally released ACh is diYcult to make and may even be
impossible in cases when release occurs from both systems. It
has been suggested that epithelial cells of the mouse trachea
release ACh upon stimulation with serotonin, thereby causing
cholinergic airway constriction (MoVatt et al. 2004). The
major Wnding leading to this conclusion was the sensitivity of
the serotonin-induced constriction to atropine, a widely used
blocker of cholinergic muscarinic receptors (MoVatt et al.
2004). In mouse bronchi, however, serotonin-induced bron-
choconstriction is fully unaVected in M2/M3 receptor double-
knockout mice that are entirely unresponsive to muscarine
itself, and this bronchoconstriction is still sensitive to atropine
(Struckmann et al. 2003; Kummer et al. 2006). Albeit this
study fully conWrmed the earlier pharmacological data
obtained on trachea it unraveled non-speciWc eVects of atro-
pine and excluded an involvement of epithelial ACh acting
upon smooth muscle muscarinic receptors in this set-up. In
general, it also has to be considered that the amount of epithe-
lial ACh is by far less than that of neuronally released ACh,
and that the smooth muscle layer is equipped with strong cho-
linolytic activity. Collectively, there is presently no direct evi-
dence for a direct action of epithelially released ACh upon
airway smooth muscle or other structures located among
smooth muscle cells or even deeper in the airway wall.
While so far there has been no experiment designed that
unequivocally allows to discriminating between epithelially
and neurally evoked cholinergic eVects in the airways, it is
plausible to assume that epithelial ACh may preferentially
reach those structures that are closest to the epithelium or
even penetrate it. Here, subepithelial airway Wbroblasts
have to be considered as potential target (cf. Fig. 1). In the
Wrst line of candidates, however, are cells of the immune
system and sensory nerve endings that both are particularly
frequent immediately underneath the basement membrane
and also are found above it between the epithelial cells.
Indeed, vagal sensory airway neurons express nAChR sub-
units, are sensitive to ACh and nicotine, and are so inti-
mately connected to the epithelium that they respond to
inhaled nicotine (Lee et al. 1993,  2007; Gu et al. 2008).
Stimulation of such Wbres causes local release of neuro-
peptides and is perceived as irritation, initiating a cough
reXex (Jinno et al. 1994; Lee et al. 2007). As such, they are
also part of the local innate defence mechanisms.
Role in disease
Dysregulation of muscarinic receptors is an important feature
of frequent airway diseases such as asthma and COPD, and
the use of muscarinic antagonists is a major strategy in phar-
macological treatment of COPD (Coulson and Fryer 2003;
Fig. 10 Scenario of a local auto-/paracrine role of epithelial ACh in
regulating various aspects on the innate mucosal defence mechanisms.
Pro-proliferative eVects both on the epithelium and on subepithelial
Wbroblasts may occur in parallel230 Histochem Cell Biol (2008) 130:219–234
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Gosens et al. 2006). While the relative contributions of neuro-
nal and non-neuronal ACh in pathomechanisms still have to
be worked out, there is agreement that both systems have to
be considered and analyzed separately (Kummer and Lips
2006; Gwilt et al. 2007). Based on the seminal Wnding that
ACh levels are increased in the skin biopsies of patients with
atopic dermatitis (Wessler et al. 2003) it has been assumed
that epithelial ACh may be increased in airway inXammatory
diseases as well, thereby contributing to activation of immune
cells and to bronchoconstriction (Barnes 2004). Direct mea-
surements, however, point to the opposite direction. The total
airway ACh content is reduced in patients suVering from cys-
tic Wbrosis (Wessler et al. 2007), and expression of the non-
neuronal ACh synthesis and release machinery is down-regu-
lated in acute allergic airway inXammation of rat and mouse
(Lips et al. 2007b). Interestingly, administration of keratino-
cyte growth factor, which is a powerful proactive agent
against various injurious stimuli, also down-regulates the pul-
monary capacity of non-neuronal ACh production, which has
been interpreted as preventing cholinergic over-stimulation
(Grau et al. 2007a). Concomitantly, the expression pattern of
individual nAChR subunits changes diVerentially, likely to
result in changes in the biological activity of ACh under such
conditions (Grau et al. 2007b).
The general stimulatory eVect of ACh on epithelial cell
proliferation, the presence of nAChR on airway epithelial
cells and the association between smoking and lung cancer
very obviously point to a possible link of the intrinsic epithe-
lial cholinergic system and the development of lung cancer.
Indeed, small cell lung cancer cells—originating from neuro-
endocrine cells of the epithelium—and squamous carcinoma
cells synthesize and release ACh, and this serves as an auto-
crine growth factor, acting both via muscarinic M3 and
nAChR receptors (Song et al. 2003, 2007). This important
Weld has been fully reviewed by Song and Spindel (2008).
Most recently, three independent groups have demonstrated
that variation in a region of 15q25.1 containing nAChR genes
coding for subunits 3, 5 and 4 contributes to lung cancer
risk (Amos et al. 2008; Hung et al. 2008; Thorgeirsson et al.
2008). Besides being activated by ACh, these receptors bind
to N-nitrosonornicotine and potential lung carcinogens.
In summary, in inXammatory airways disease the epithe-
lial cholinergic system undergoes plastic changes which
either may be part of the pathogenetic process or reXect
secondary changes. In lung cancer, however, there is grow-
ing evidence that disturbances of this system directly con-
tribute to the development of the disease.
Conclusion
Among the various airway cell types, there is cell type-spe-
ciWc expression and subcellular distribution of the molecu-
lar pathways of ACh release, suggesting both luminal and
basolateral release. Although solid direct data discriminat-
ing between epithelially and neurally evoked cholinergic
eVects are very scarce the scenario as known so far strongly
suggests a local auto-/paracrine role of epithelial ACh in
regulating various aspects on the innate mucosal defence
mechanisms, including mucociliary clearance, regulation of
macrophage function and modulation of sensory nerve Wbre
activity (Fig. 10). The proliferative eVects of ACh gain
importance in ACh receptor disorders conferring suscepti-
bility to lung cancer. Noteworthy, such a role is particularly
well supported for small lung cell carcinoma originating
from neuroendocrine cells that show a particularly strong
expression of cholinergic traits. In allergic inXammatory
lung disease, the expression pattern of the non-neuronal
cholinergic system is greatly altered but it is currently not
clear to which extent this may contribute to the pathoge-
netic process. The cell type-speciWc molecular diversity of
the ACh synthesis and release machinery is highly likely to
imply that non-neuronal ACh release is (a) diVerently regu-
lated than neuronal ACh release and (b) can be speciWcally
targeted by appropriate drugs. As such the non-neuronal
cholinergic system of the airways may emerge as new ther-
apeutic target in treatment of proliferative and inXamma-
tory airway diseases.
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